Hippocampus‐avoidance whole‐brain radiation therapy with a simultaneous integrated boost for multiple brain metastases. Issue 11 (6th March 2020)

• Record Type: Journal Article
• Authors: Popp, Ilinca; Rau, Stephan; Hintz, Mandy; Schneider, Julius; Bilger, Angelika; Fennell, Jamina Tara; Heiland, Dieter Henrik; Rothe, Thomas; Egger, Karl; Nieder, Carsten; Urbach, Horst; Grosu, Anca Ligia
• Is Part Of: Cancer. Volume 126:Issue 11(2020)
• Page Start: 2694
• Page End: 2703
• Publication Date: 2020-03-06
• Subjects: brain metastases -- hippocampus avoidance -- neurocognitive function -- whole‐brain radiation therapy; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.32787
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : Background: The current study was aimed at investigating the feasibility of hippocampus‐avoidance whole‐brain radiation therapy with a simultaneous integrated boost (HA‐WBRT+SIB) for metastases and at assessing tumor control in comparison with conventional whole‐brain radiation therapy (WBRT) in patients with multiple brain metastases. Methods: Between August 2012 and December 2016, 66 patients were treated within a monocentric feasibility trial with HA‐WBRT+SIB: hippocampus‐avoidance WBRT (30 Gy in 12 fractions, dose to 98% of the hippocampal volume ≤ 9 Gy) and a simultaneous integrated boost (51 or 42 Gy in 12 fractions) for metastases/resection cavities. Intracranial tumor control, hippocampal failure, and survival were subsequently compared with a retrospective cohort treated with WBRT via propensity score matching analysis. Results: After 1:1 propensity score matching, there were 62 HA‐WBRT+SIB patients and 62 WBRT patients. Local tumor control (LTC) of existing metastases was significantly higher after HA‐WBRT+SIB (98% vs 82% at 1 year; P = .007), whereas distant intracranial tumor control was significantly higher after WBRT (82% vs 69% at 1 year; P = .016); this corresponded to higher biologically effective doses. Intracranial progression‐free survival (PFS; 13.5 vs 6.4 months; P = .03) and overall survival (9.9 vs 6.2 months; P = .001) were significantly better in the HA‐WBRT+SIB cohort. Four patients (6.5%) developed hippocampal metastases after hippocampus avoidance. The neurologic death rate after HA‐WBRT+SIB was 27.4%. Conclusions: HA‐WBRT+SIB can be an efficient therapeutic option for patients with multiple brain metastases and is associated with improved LTC of existing metastases, higher intracranial PFS, a reduction of the neurologic death rate, and an acceptable risk of radiation necrosis. The therapy has the potential to prevent neurocognitive adverse effects, which will be further evaluated in the multicenter, phase 2 HIPPORAD trial. Abstract : The current trial provides information on the first and largest cohort to date treated with hippocampus‐avoidance whole‐brain radiation therapy with a simultaneous integrated boost (HA‐WBRT+SIB) for multiple brain metastases. HA‐WBRT+SIB is an efficient therapeutic option and is associated with improved local tumor control of existing metastases, higher intracranial progression‐free survival, a reduction of the neurologic death rate, and an acceptable risk of radiation necrosis.